IPSEY

PINK Ipsen SA Sponsored ADR

Nov 5, 2026 · 7:35 PM ET EOD Market Closed

$43.67 ↓ -0.05 (-0.12%) Trading Down from the previous close of $43.72, and at the day’s high of $43.67

YTD change: +20.09%
vs 20-day SMA: +3.68%
vs 200-day SMA: +12.54%

Price ranges

Previous day

$43.67 $43.67

open $43.67 close $43.67

+$0.00 (+0.00%)

Today

$43.67 $43.67

open $43.67 now $43.67

+$0.00 (+0.00%)

Past week

$42.01 $44.46

from $42.60 now $43.67

+$1.07 (+2.50%)

Past month

$39.12 $44.75

from $44.75 now $43.67

-$1.08 (-2.42%)

This year

$34.34 $51.10

from $36.36 now $43.67

+$7.31 (+20.09%)

Price & Performance

-6.93 (-13.70%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

N/A

The stock is 14.5% away from all-time highs of $51.10
IPSEY is up 20% since the beginning of the year
IPSEY is up 21% over the past 12 months
IPSEY is down 2% over the past 1 month

IPSEY reads n/a: price sits above both the 20- and 200-day averages, the 12-month move is +23.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes

EPS $42.6829

Earnings momentum N/A Quarterly EPS growth

Quarterly change N/A

Valuation

P/E ratio N/A

Enterprise value $13.1B

Beta 0.19

Balance sheet & scale

Income$605.9K

Revenue$4.7B

Cash$2.3B

Debt$1.1M

Income / Debt 0.55×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $14.4B

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,417.99	+0.61%
JNJ	Johnson & Johnson	$276.32	+3.81%
ABBV	AbbVie, Inc.	$294.83	+3.09%
MRK	Merck & Co., Inc.	$150.36	+3.93%
RHHBY	Roche Holding Ltd Sponsored ADR	$60.94	+2.97%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.